Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
OLMA 
Olema Pharmaceuticals Inc (OLMA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: OLMA (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
8 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $25
1 Year Target Price $25
| 5 | Strong Buy |
| 3 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 13.92% | Avg. Invested days 32 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 361.02M USD | Price to earnings Ratio - | 1Y Target Price 25 |
Price to earnings Ratio - | 1Y Target Price 25 | ||
Volume (30-day avg) 8 | Beta 1.93 | 52 Weeks Range 2.86 - 13.93 | Updated Date 08/15/2025 |
52 Weeks Range 2.86 - 13.93 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.97 |
Earnings Date
Report Date 2025-08-12 | When - | Estimate -0.3761 | Actual -0.51 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -30.86% | Return on Equity (TTM) -49.72% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 3858570 | Price to Sales(TTM) - |
Enterprise Value 3858570 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -3.33 | Shares Outstanding 68634304 | Shares Floating 53866798 |
Shares Outstanding 68634304 | Shares Floating 53866798 | ||
Percent Insiders 3.31 | Percent Institutions 99.58 |
Upturn AI SWOT
Olema Pharmaceuticals Inc
Company Overview
History and Background
Olema Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for womenu2019s cancers. Founded in 2017, the company is relatively young, with key milestones including the development of its lead candidate, palazestrant (OP-1250), and its subsequent clinical trials.
Core Business Areas
- Oncology Drug Development: Focuses on developing and commercializing targeted therapies for women's cancers, particularly estrogen receptor-positive (ER+) breast cancer.
Leadership and Structure
Sean P. Bohen, M.D., Ph.D., serves as the President and Chief Executive Officer. The organizational structure includes research and development, clinical operations, and commercial functions.
Top Products and Market Share
Key Offerings
- Palazestrant (OP-1250): A complete estrogen receptor (ER) antagonist (CERAN) and selective ER degrader (SERD) being developed for the treatment of ER+ breast cancer. Currently in clinical trials. Competitors include existing SERDs like elacestrant (Orserdu) from Menarini/Stemline and aromatase inhibitors.
Market Dynamics
Industry Overview
The oncology drug market is a large and growing market driven by an aging population and advances in cancer treatment. The breast cancer therapeutics market is a significant segment within oncology. There is a demand for therapies that overcome resistance to existing treatments.
Positioning
Olema aims to address unmet needs in ER+ breast cancer with Palazestrant, targeting patients who have developed resistance to existing therapies. Its competitive advantage lies in the potential for Palazestrant to be a more complete ER antagonist and degrader.
Total Addressable Market (TAM)
The global breast cancer therapeutics market is expected to reach hundreds of billions of dollars. Olema is positioned to capture a portion of this market by addressing patients with advanced ER+ breast cancer who have failed other lines of therapy.
Upturn SWOT Analysis
Strengths
- Novel CERAN/SERD mechanism of action
- Potential to address resistance to existing therapies
- Experienced management team
- Strong cash position
Weaknesses
- Early stage clinical development
- Dependence on a single lead candidate
- Limited commercial infrastructure
- Lack of revenue generation
Opportunities
- Positive clinical trial results
- Partnerships with larger pharmaceutical companies
- Expansion into other cancer types
- Regulatory approvals
Threats
- Clinical trial failures
- Competition from existing and emerging therapies
- Regulatory hurdles
- Patent challenges
Competitors and Market Share
Key Competitors
- SNY (Sanofi)
- PFE (Pfizer)
- AZN (AstraZeneca)
Competitive Landscape
Olema is a smaller player compared to larger pharmaceutical companies. Its advantage lies in its specific focus and novel mechanism of action.
Growth Trajectory and Initiatives
Historical Growth: Olema's historical growth is characterized by R&D progress and clinical trial advancements.
Future Projections: Future growth depends on the success of Palazestrant and pipeline expansion. Analyst estimates vary based on clinical trial outcomes.
Recent Initiatives: Recent initiatives include initiating and progressing clinical trials for Palazestrant and exploring new indications and combinations.
Summary
Olema Pharmaceuticals is a clinical-stage biopharmaceutical company with a promising lead candidate, Palazestrant, targeting ER+ breast cancer. While the company is pre-revenue and faces risks associated with clinical development, it has a novel mechanism of action and experienced management. Success hinges on positive clinical trial results and securing partnerships or regulatory approvals. The company needs to watch out for larger pharmaceutical companies who might create competing products.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Olema Pharmaceuticals Investor Relations
- SEC Filings (10-K, 10-Q)
- Industry Analyst Reports
- ClinicalTrials.gov
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market share data is approximate and may vary based on source and definition. Financial data is based on publicly available information and analyst estimates, which are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Olema Pharmaceuticals Inc
Exchange NASDAQ | Headquaters San Francisco, CA, United States | ||
IPO Launch date 2020-11-19 | President, CEO & Director Dr. Sean P. Bohen M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 96 | Website https://olema.com |
Full time employees 96 | Website https://olema.com | ||
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. The company's lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; OPERA-01, the pivotal Phase 3 clinical trial of palazestrant as a monotherapy in second/third-line ER+/HER2- metastatic breast cancer; and palazestrant with CDK4/6 inhibitors palbociclib and ribociclib, a phosphatidylinositol 3 kinase alpha (PI3Ka) inhibitor alpelisib, and with an mTOR inhibitor everolimus that is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer. It also develops OP-3136, an orally-available small molecule that potently and selectively inhibits KAT6 for patients with ER+/HER2- metastatic breast cancer and other cancers which is in Phase 1 clinical trial. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.